Friday, May 28, 2021

Bajaj Healthcare launches drug to treat black fungus infection in COVID-19 patients

Bajaj Healthcare launches drug to treat black fungus infection in COVID-19 patients The company has received approval from FDA (Food and Drugs Administration) Gandhi Nagar, Gujarat (India), to manufacture and market Posaconazole API as approved medication for treating Mucormycosis in India, Bajaj Healthcare said in a regulatory filing.

from Moneycontrol Business News https://ift.tt/34pXZ7Y
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Zepto IPO, Swiggy QIP bad news for Eternal investors? Jefferies analysts decode

Jefferies has reiterated its Buy rating on Eternal with a target price of Rs 480, citing strong growth prospects, improving unit economics a...